Tracing the rise of tumor chemotherapy from the discovery of the first anticancer drug, nitrogen mustard, 1 to the advent of molecular approaches sheds light on the problem of drug resistance which has dogged oncology for the past half century. A number of strategies have been advised to combat the war against cancer, eg modulators of drug resistance, noncross-resistant drug derivatives, high-dose therapy, hematopoietic stem cell transplantation, and supportive gene therapy protocols. Another way is the a priori diagnosis of drug-resistant tumors. In the past three decades efforts have been undertaken to determine the resistance profiles of tumors by testing drug response in vitro. 2, 3 The advances in cell and molecular biology have opened new avenues for the characterization of drug-resistant tumors. Among the plethora of resistance mechanisms, MDR1, MRP, LRP and TOPO II attracted the attention of oncologists and the transfer from the bench to the bed is a straightforward requirement. Several laboratories from the United States and Europe have teamed up under the leadership of WT Beck (University of Illinois at Chicago, USA) and JP Marie (Hô pital d'Hotel-Dieu, Paris, France), respectively, in an effort to advise a suitable methodology for the detection of MDR in clinical routine laboratory diagnostics. 4, 5 In contrast to cells with high levels of drug resistance, the balance of results presented from these workshops did rather not speak Correspondence: T Efferth; Fax: +49-9131-8526493 Received 28 June 1999; accepted 7 July 1999 in favor of the detection of clinically relevant low-level resistance. To define consensus recommendations for the standardized of detection of resistance genes expressed in low amounts is therefore more difficult as initially estimated. 6 Methods to detect protein or mRNA expression are more at the center of interest. Protein detection by immunohistochemistry or flow cytometry and mRNA detection by reverse transcription-polymerase chain reaction (RT-PCR) may be more suited for clinical routine applications than more sophisticated assays such as Western blotting, Northern blotting, or RNAse protection assay. Immunohistochemistry, however, came under debate with respect to its reproducibility to detect low levels of P-glycoprotein expression in large multicentric evaluations. 4, 5 Although immunohistochemistry is a morphological means with inherent limitations concerning quantitative evaluation, many semiquantitative immunohistochemical studies provided evidence for the prognostic value of P-gp for patients' survival or a disease-free interval and corroboration has come from investigations measuring mRNA expression. [7] [8] [9] [10] This speaks of some validity of immunohistochemistry in general. Nevertheless, the considerable inter-and intralaboratory variations presented at the American and French workshops hamper a reliable clinical routine application. A close inspection of immunohistochemical methodology may draw the attention to some problems.
Comparisons to find an obliging consensus of what are the most suitable antibodies and PCR primers may facilitate methodological standardization. A lack of cross-reactivity to unspecific epitopes as observed with MRK 16, UIC2 and 4E3 antibodies against P-glycoprotein is an indispensable prerequisite. It may be helpful to use a cocktail of antibodies, if monospecific antibodies recognizing internal and external epitopes of P-gp produce differing results under comparable experimental conditions. Although less recognized as yet, the same problem may apply to PCR primers. Sugawara et al 11 found primer-dependent amplifications of the MDR1 message which differ both qualitatively and quantitatively.
The polytopic nature of P-gp 12 may contribute to epitope masking among different tumor samples. Messenger RNA analyses are not confronted by this problem. Cumber et al 13 found a considerable degree of discordance between the results obtained by immunohistochemistry and RT-PCR in a set of leukemia samples which disappeared, if 'hidden' epitopes were demasked by neuraminidase. Epitope masking, however, does not explain inter-and intralaboratory discrepancies of immunohistochemistry.
In contrast to many other methods, immunohistochemistry is generally not performed in an automated manner and staining results may vary with individual technical skills. Automated robotic workstations are now commercially available devices for immunohistochemistry. 14 16 the quantitation of RT-PCR products has been a matter of discussion as well. Real-time PCR techniques have recently been developed which may improve precise quantitation of mRNA expression and the determination of thresholds of gene expression.
Approaches for the simultaneous detection of protein and mRNA expression (ie immunohistochemistry together with in situ hybridization or in situ PCR) enable the co-localization of protein and corresponding mRNA at the single cell level. This may facilitate the interpretation of expression profiles. This approach has been successfully applied for several proteins/mRNAs not involved in drug resistance. 17, 18 Experiences with such double labeling techniques for P-gp, MRP, or LRP are still limited as of yet.
Measuring uptake, efflux, or intracellular distribution of fluorescing or radioactively labeled cytostatic drugs or other P-gp substrates (rhodamine 123, 99m Tc Sestamibi etc) seem to offer attractive alternatives. Interestingly, a monoclonal antibody, UIC2, shows increased reactivity with P-glycoprotein upon conformational changes of the protein during drug transport. A recently developed flow cytometric UIC2 shift assay detects pumping activities of P-glycoprotein and is more sensitive than conventional flow cytometric P-glycoprotein stainings. 19 A drawback of functional assays, however, is the limitation to vital single cell tumors.
Analyses of drug resistance genes at the DNA level are less appropriate for chemosensitivity testing. MDR1, MRP, or LRP gene amplifications or point mutations are rare in clinical tumor samples with low degrees of drug resistance. 20 Microsatellite instability as a consequence of deficient DNA repair may be of predictive value for drug resistance testing. Nucleotide excision repair and base mismatch repair are not only relevant for response of tumor cells towards alkylating agents and platinum derivatives but also for drugs involved in MDR, eg doxorubicin. 21 Global surrogate assays to measure chemosensitivity of tumor cells 2 are not generally established in clinical routine diagnosis. Recent experimental evidence explained some pitfalls of these methods. Cytostatic drugs or ionizing radiation induce cell cycle checkpoint arrests which provide ample time to repair otherwise detrimental DNA damage. Tumor cells with intact checkpoint function stop growth, but will regrow after withdrawal of drug exposure. By contrast, checkpoint-deficient tumor cells die. 22 The p21 WAF1/CIP1 gene is a key molecule for checkpoint function. Clonogenic survival assays do not discriminate between growth arrest of drug resistant checkpoint-proficient and growth inhibition of drugsensitive checkpoint-deficient cells. Both situations preclude colony growth thus feigning chemosensitivity. Flaws with drugs not acting on DNA such as the Vinca alkaloids have also been analyzed. 23 A component of cell culture media, riboflavin, was shown to react with Vinca alkaloids upon illumination (500 nm) thereby triggering the degradation in in vitro assays.
The recognition of apoptosis as a major player of antitumor drug cytotoxicity awaked some hopes for a more specific determination of chemosensitivity. Leukemic cells showed bell-shaped dose-response curves for apoptosis due to a switch from apoptosis to necrosis with increasing drug doses. 24 The position of the bell-shaped curve on the drug concentration and time scales and the number of apoptotic cells varied among patient samples according to each tumor's individual drug sensitivity. This tends to limit clinical practicability. A recently developed microculture kinetic (MiCK) assay may overcome these pitfalls. 25 The spectrofluorometric MiCK assay provides an automatic means to monitor anthracyclineinduced apoptosis of leukemic cells in a time-and concentration-dependent manner.
The concepts discussed thus far in this paper focus on the impact of a single resistance gene for drug resistance in a larger number of tumors. Such approaches may be described as 'horizontal screening' for drug resistance. Vice versa, 'vertical screening' would aim to detect a larger number of resistance mechanisms in few tumors. A panoply of genes acting both upstream or downstream of drug-target interaction sites may all contribute to drug resistance and hamper the evaluation of impact of any single resistance gene. Genome-wide scanning of genetic instabilities and gene expression profiles will achieve importance for the diagnosis of tumors with poor prognosis. While the cell's genome is rather static in nature, the expression and functions of proteins are extremely dynamic depending on environmental conditions. Proteome analyses as counterparts of genome analyses allow determination of quality and quantity of expressed proteins as well as their post-translational modifications under well-defined experimental conditions. Proteome comparisons between sensitive and resistant tumor cells will enable the identification of novel resistance mechanisms. It is not beyond the limits of expectation that genomics and proteomics will emerge as predictors for the response of tumors towards chemotherapeutical agents. 26 With such novel approaches of molecular pharmacology in place, individual cytostatic treatment schedules for each patient may pave new ways to defeat clinical drug resistance.
